InsiderTrades.com logo
Mayukh Sukhatme net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Mayukh Sukhatme Biography and Net Worth

President and Chief Investment Officer of Roivant Sciences

Mayukh Sukhatme is President and Chief Investment Officer of Roivant, and also serves on our Board of Directors.  Dr. Sukhatme is responsible foridentifying, performing diligence on, devising development strategies for, and transacting on new therapeutic programs for Roivant. Dr. Sukhatme also informs Roivant’s view of its existing biopharmaceutical subsidiary companies for capital allocation decisions across the Roivant portfolio. Dr. Sukhatme joined Roivant in 2015 and previously served as President of Roivant Pharma and as our Chief Business Officer. Programs that Dr. Sukhatme has in-licensed or acquired for Roivant have produced all 10 of our positive Phase 3 studies and have garnered 6 FDA approvals. From 2000 to 2015, Dr. Sukhatme was a healthcare-focused analyst and portfolio manager for several large institutional investment firms, including both public markets and venture capital firms. His principal focus was on development-stage biotechnology and pharmaceutical companies, where he led diligence and investment decisions on numerous companies and pharmaceutical compounds across a wide variety of therapeutic areas. Dr. Sukhatme earned his M.D. from Harvard Medical School and his B.S. in Biology and B.S. in Literature from MIT.

What is Mayukh Sukhatme's net worth?

The estimated net worth of Mayukh Sukhatme is at least $199.01 million as of December 24th, 2024. Dr. Sukhatme owns 18,836,547 shares of Roivant Sciences stock worth more than $199,008,119 as of March 26th. This net worth estimate does not reflect any other assets that Dr. Sukhatme may own. Additionally, Dr. Sukhatme receives an annual salary of $1,720,000.00 as President and Chief Investment Officer at Roivant Sciences. Learn More about Mayukh Sukhatme's net worth.

How old is Mayukh Sukhatme?

Dr. Sukhatme is currently 48 years old. There are 5 older executives and no younger executives at Roivant Sciences. The oldest executive at Roivant Sciences is Ms. Marianne L. Romeo, Head of Global Transactions & Risk Management, who is 56 years old. Learn More on Mayukh Sukhatme's age.

What is Mayukh Sukhatme's salary?

As the President and Chief Investment Officer of Roivant Sciences Ltd., Dr. Sukhatme earns $1,720,000.00 per year. The highest earning executive at Roivant Sciences is Mr. Matthew Gline, CEO & Director, who commands a salary of $1,770,000.00 per year. Learn More on Mayukh Sukhatme's salary.

How do I contact Mayukh Sukhatme?

The corporate mailing address for Dr. Sukhatme and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at ir@roivant.com. Learn More on Mayukh Sukhatme's contact information.

Has Mayukh Sukhatme been buying or selling shares of Roivant Sciences?

Mayukh Sukhatme has not been actively trading shares of Roivant Sciences within the last three months. Most recently, Mayukh Sukhatme sold 689,495 shares of the business's stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.01, for a transaction totalling $8,280,834.95. Following the completion of the sale, the executive now directly owns 18,836,547 shares of the company's stock, valued at $226,226,929.47. Learn More on Mayukh Sukhatme's trading history.

Who are Roivant Sciences' active insiders?

Roivant Sciences' insider roster includes Matthew Gline (CEO), Rakhi Kumar (CAO), Keith Manchester (Director), Mayukh Sukhatme (President and Chief Investment Officer), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.

Are insiders buying or selling shares of Roivant Sciences?

In the last year, Roivant Sciences insiders bought shares 1 times. They purchased a total of 16,845,010 shares worth more than $336,900,200.00. In the last year, insiders at the sold shares 18 times. They sold a total of 6,815,479 shares worth more than $79,086,208.08. The most recent insider tranaction occured on March, 24th when COO Eric Venker sold 434,478 shares worth more than $4,701,051.96. Insiders at Roivant Sciences own 7.9% of the company. Learn More about insider trades at Roivant Sciences.

Information on this page was last updated on 3/24/2025.

Mayukh Sukhatme Insider Trading History at Roivant Sciences

See Full Table

Mayukh Sukhatme Buying and Selling Activity at Roivant Sciences

This chart shows Mayukh Sukhatme's buying and selling at Roivant Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$10M$0$10MTotal Insider BuyingTotal Insider Selling

Roivant Sciences Company Overview

Roivant Sciences logo
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Read More

Today's Range

Now: $10.56
Low: $10.53
High: $10.70

50 Day Range

MA: $10.78
Low: $10.17
High: $11.37

2 Week Range

Now: $10.56
Low: $9.96
High: $13.06

Volume

1,888,540 shs

Average Volume

5,630,224 shs

Market Capitalization

$7.53 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26